AMRX:NYE-Amneal Pharmaceuticals, Inc. Class A Common Stock (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 8.49

Change

0.00 (0.00)%

Market Cap

USD 2.63B

Volume

2.48M

Analyst Target

USD 4.11
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.69B
HLN Haleon plc

N/A

USD 47.33B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.37B
CTLT Catalent Inc

N/A

USD 10.83B
ELAN Elanco Animal Health

N/A

USD 7.59B
BHC Bausch Health Companies Inc

N/A

USD 2.33B
CPHI China Pharma Holdings Inc

N/A

USD 3.04M
YCBD cbdMD Inc

N/A

USD 2.14M
EBS Emergent Biosolutions Inc

N/A

N/A

ETFs Containing AMRX

LNGG Listed Funds Trust 10.84 % 0.00 %

N/A

USD 0.74M
ZFC:CA BMO SIA Focused Canadian .. 6.77 % 0.00 %

N/A

CAD 0.06B
MVR:AU VanEck Vectors Australian.. 6.39 % 0.00 %

N/A

USD 0.43B
AUCO:SW L&G Gold Mining UCITS ETF.. 5.61 % 0.00 %

N/A

N/A
ROYA 5.38 % 0.00 %

N/A

N/A
ETLX:XETRA L&G Gold Mining UCITS ETF 5.37 % 0.00 %

N/A

USD 0.13B
QRE:AU Beta Shares S&P/ASX 200Re.. 4.79 % 0.00 %

N/A

USD 0.21B
OZR:AU SPDR S&P/ASX 200 Resource.. 4.54 % 0.00 %

N/A

USD 0.17B
HDGE:CA Accelerate Absolute Retur.. 3.68 % 0.00 %

N/A

CAD 0.03B
HAL:CA Global X Active Canadian .. 3.26 % 0.78 %

N/A

CAD 0.12B
OAEM OneAscent Emerging Market.. 3.11 % 0.00 %

N/A

N/A
FEM First Trust Emerging Mark.. 1.27 % 0.80 %

N/A

USD 0.41B
DLS WisdomTree International .. 0.00 % 0.58 %

N/A

N/A
RING iShares MSCI Global Gold .. 0.00 % 0.39 %

N/A

USD 0.55B
IOGP:LSE iShares Oil & Gas Explora.. 0.00 % 0.00 %

N/A

N/A
SPOG:LSE iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ETLX:F L&G Gold Mining UCITS ETF 0.00 % 0.00 %

N/A

N/A
EXXW:F iShares Dow Jones Asia Pa.. 0.00 % 0.00 %

N/A

N/A
IQQX:F iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
IS0D:F iShares Oil & Gas Explora.. 0.00 % 0.00 %

N/A

N/A
EXXW:XETRA iShares Dow Jones Asia Pa.. 0.00 % 0.00 %

N/A

USD 0.29B
IQQX:XETRA iShares Asia Pacific Divi.. 0.00 % 0.00 %

N/A

USD 0.40B
IAPD:SW iShares Asia Pacific Divi.. 0.00 % 0.00 %

N/A

USD 0.42B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.87% 82% B 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.87% 82% B 95% A
Trailing 12 Months  
Capital Gain 129.46% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 129.46% 100% F 99% N/A
Trailing 5 Years  
Capital Gain 188.78% 100% F 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 188.78% 100% F 93% A
Average Annual (5 Year Horizon)  
Capital Gain 33.22% N/A N/A 91% A-
Dividend Return 33.22% N/A N/A 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 86.83% N/A N/A 9% A-
Risk Adjusted Return 38.25% N/A N/A 57% F
Market Capitalization 2.63B 50% F 69% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.